Subjective attitude to risperidone long-acting injectable (RLAI): Results from a long-term Italian study in subjects with schizophrenia or schizoaffective disorder

被引：0

作者：

Rossi, A. ^{[1
]}

Bernareggi, M. M. ^{[2
]}

Giustra, M. G. ^{[2
]}

机构：

[1] Univ Laquilo, Dept Expt Med, Laquila, Italy

[2] Janssen Cilag SpA, Risperidone Long Acting Trial Italian Invest, Med Affairs, Milan, Italy

来源：

EUROPEAN PSYCHIATRY | 2008年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

引用

页码：S167 / S167

页数：1

共 50 条

[31] MIRROR IMAGE STUDIES OF RISPERIDONE LONG-ACTING INJECTION FOR CHRONIC SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER
Einarson, T. R.
Jensen, R.
Hemels, M.
VALUE IN HEALTH, 2012, 15 (07) : A334 - A334
[32] A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone
Vieta, Eduard
Nieto, Evaristo
Autet, Aurea
Rosa, Adriane R.
Goikolea, Jose M.
Cruz, Nuria
Bonet, Pere
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2008, 9 (03): : 219 - 224
[33] Long-acting injectable (LAI) antipsychotics in the long-term treatment of schizophrenia
Fleischhacker, Wolfgang
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 321 - 322
[34] Risperidone long-acting injection (RLAI)-related sexual dysfunction in outpatients with schizophrenia
Grosic, V.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 93 - 93
[35] Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder - Randomised, controlled, open-label study
Keks, Nicholas A.
Ingham, Michael
Khan, Akbar
Karcher, Keith
BRITISH JOURNAL OF PSYCHIATRY, 2007, 191 : 131 - 139
[36] Young patients (18-30 years) with schizophrenia and schizoaffective disorder: Results of direct switching to long-acting injectable risperidone (Stormi trial)
Saleem, PT
Firmino, H
Parellada, E
SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 176 - 176
[37] Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial (vol 35, pg 2367, 2010)
Gaebel, Wolfgang
Schreiner, Andreas
Bergmans, Paul
de Arce, Rosario
Rouillon, Frederic
Cordes, Joachim
Eriksson, Lars
Smeraldi, Enrico
NEUROPSYCHOPHARMACOLOGY, 2011, 36 (02) : 548 - 548
[38] Does Long-Acting Injectable Risperidone (RLAI) Reduce Relapse and Rehospitalization in Patients with Frequently Relapsing Bipolar Disorder?
Bobo, William V.
Epstein, Richard A.
Lynch, Alan
Patton, Tynya D.
Bossaller, Nicholas A.
Shelton, Richard C.
BIOLOGICAL PSYCHIATRY, 2011, 69 (09) : 37S - 37S
[39] Interim-analysis of a long-term treatment study with long-acting injectable risperidone and oral second generation antipsychotics in schizophrenia
Ibach, B.
Schreiner, A.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S437 - S437
[40] Long-term cognitive effects of risperidone in patients with schizophrenia and schizoaffective disorder
Martinez, RA
Harvey, PD
Green, MF
Meltzer, HY
SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 237 - 238

← 1 2 3 4 5 →